Peripheral T-cell lymphomas (PTCL) are rare and heterogeneous lymphomas comprising numerous histologies.

Radiation Therapy and HL

The use of radiation therapy (RT) has been shown to improve 10-year survival rates in patients with stage I-II Hodgkin’s lymphoma (HL). However, the use of RT in this patient population declined from 56% to 41% between 1998 and 2011. 

EU Approves Idelalisib

Idelalisib has been approved by the European Union for the treatment of patients with chronic lymphocytic leukaemia (CLL) and follicular lymphoma (FL). Idelalisib, an oral therapy, is an inhibitor of P13K delta, a protein that is overexpressed in many B-cell malignancies.

Improved Survival in Europe

Findings from a retrospective observational study that included patients diagnosed with haematological malignancies from 20 European countries showed that survival increased for most haematological malignancies.

Idelalisib and CLL

A phase III trial examining the use of idelalisib in patients with chronic lymphocytic leukaemia (CLL) will be stopped early as an interim analysis demonstrated significant improvement in progression-free survival, the primary end point.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Did you know research has demonstrated that confidence, which stems from information and support, plays a significant role in patients’ positive healthcare experiences and outcomes?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.